FDA-mandated CAR-T monitoring period could be halved, say researchers

FDA-mandated CAR-T monitoring period could be halved, say researchers

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.

​Medical Xpress – latest medical and health news stories

Read More


Discover more from Nurse Unity Chats

Subscribe to get the latest posts sent to your email.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *